A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
Professor James Paton, Director of the University of Adelaide’s Research Centre for Infectious Diseases and his team have been working on a vaccine for Streptococcus pneumoniae (the pneumococcus) that could save two million lives globally a year and address the overuse of antibiotics that leads to resistance.
“The pneumococcus is the biggest bacterial killer on the planet. It’s the most common cause of pneumonia, which is responsible for about 20 per cent of deaths from all causes in children under 5 years in developing countries. Globally, the pneumococcus accounts for about two million deaths a year,” says Professor Paton.
Streptococcus pneumoniae, which is principally spread through close contact with infected but asymptomatic carriers, is the leading cause of sinus and ear infections, meningitis, sepsis and pneumonia. Ear infections are one of the most common childhood illnesses that are habitually treated with antibiotics, contributing to increasing bacterial resistance.
“Vaccinating people against Streptococcus pneumoniae would help to ameliorate the global challenge of increasing bacterial resistance to antibiotics,” says Professor Paton.
“The problem with the existing pneumococcal vaccine is that it targets the outside coat of complex carbohydrates – of which there are 98 structurally distinct types. The current vaccine costs about $150 a dose and only covers 13 types.
“What we have done is to remove this coat to expose all the surface proteins that are common to all pneumococcal types. The body mounts an immune response to these surface proteins if previously exposed or vaccinated.”
Sixteen months ago, Adelaide-based GPN Vaccines Pty Ltd was created to develop this novel “whole bacterial” vaccine (Gamma-PNTM) against Streptococcus pneumoniae. The company has already secured investment from local angel investors as well as a major grant from the National Health & Medical Research Council and a Commercialisation grant from the South Australian Government.
GPN Vaccines has now raised a further AUS$1.1 million from international and Australian-based investors that will be used for preclinical evaluation of the Gamma-PNTM vaccine. Toxicity tests will be carried out as well as the scale-up clinical grade manufacture of the vaccine in readiness for testing in a first-in-human clinical trial.
Learn more: STEP FORWARD FOR PNEUMONIA VACCINE DEVELOPMENT
The Latest on: Pneumonia
[google_news title=”” keyword=”pneumonia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pneumonia
- Omics analysis identifies new biomarkers for predicting mortality in patients with pneumoniaon September 22, 2023 at 2:09 pm
Community-acquired pneumonia (CAP) is a major infectious disease worldwide and contributes to high mortality and massive economic burden. Hospital mortality among the severe CAP (SCAP) remains high, ...
- Manipur violence: Infant taking shelter in relief camp dies of pneumonia in Churachandpur hospitalon September 22, 2023 at 6:43 am
In an unfortunate incident, a one-year-old girl from a relief camp located in Churachandpur district died on September 22 at a government hospital.
- Cough analysis as a tool to predict severe pneumonia in COVID-19 patientson September 21, 2023 at 7:23 pm
While most individuals impacted by COVID-19 experience milder symptoms and recover within a few weeks, the global pandemic caused by the SARS-CoV-2 virus continues to pose a significant health ...
- Sum 41's Deryck Whibley Still Bedridden, Having Trouble Breathing After Pneumonia Hospitalizationon September 20, 2023 at 11:33 am
The Sum 41 frontman took to Instagram days after he was discharged from the hospital after a bout of pneumonia, to update fans on his health condition as he continues to fight the scary sickness.
- Sum 41's Deryck Whibley Says He's 'Not Out of the Woods Yet' After Being Hospitalized For Pneumoniaon September 20, 2023 at 9:22 am
Sum 41 star Deryck Whibley shared an update on his health on Instagram Tuesday, revealing that he's "still bedridden, having a hard time breathing, tight chest pains and some pretty wild fever dreams, ...
- Sum 41’s Deryck Whibley Gives Update After Pneumonia Hospitalization: ‘Not Out of the Woods Yet’on September 20, 2023 at 8:25 am
Sum 41 frontman Deryck Whibley is 'staying positive' but 'not out of the woods yet' after he was hospitalized for pneumonia ...
- Sum 41’s Deryck Whibley Gives Health Update After Scary Pneumonia Hospitalization: ‘Not Out of the Woods Yet’on September 20, 2023 at 6:07 am
The singer says he's trying his best to be ready for his band's set at the When We Were Young festival next month.
- Sum 41’s Deryck Whibley Recovering After Hospitalization for Pneumonia, Possible Heart Failureon September 19, 2023 at 5:13 pm
On Sunday, the frontman’s wife shared an update on his condition, writing: “The pressure and strain on his heart and lungs has improved and he is able to breath without as much ...
- Sum 41's Deryck Whibley Discharged from Hospital After 'Responding So Well' to Pneumonia Treatments, Wife Sayson September 18, 2023 at 2:12 pm
Her work has previously appeared on Daily Bruin. Phillip Faraone/Getty Sum 41 singer Deryck Whibley has been discharged from the hospital after “responding so well to his treatments” for pneumonia, ...
- Xacduro Now Available for Pneumonia Caused by Acinetobacteron September 18, 2023 at 10:13 am
Xacduro ® (sulbactam for injection; durlobactam for injection) is now available for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), ...
via Bing News